Connect to other sites within the UBM Medica Network
Incretin Therapy Side Effects Linked to Age, No Metformin Use
GI side effects can lead patients to stop GLP-1 agonist therapy. Identifying risk factors for these adverse events could help improve patient selection.
GLP-1 Agonist Fails to Improve Coronary Flow Reserve in New Study
Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.
SGLT2 Inhibitors: Check Your A1c and BPs
Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.
Dapagliflozin Plus Exenatide: Better Weight Loss Together?
What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?
Why Do Endocrinologists Burn Out?
Our endo blogger has her theories about why doing what you thought you loved just seems to sap your soul.
A 61-year-old Man with Diabetes and Resistant Hypertension
There are several reasonable options for intensifying this patient's blood pressure treatment. Which one is optimal, though, given his labs and concomitant meds?
Inflammation in Diabetes: What Role for Glucose-lowering Drugs?
Some key classes of antidiabetes agents could play a dual physiologic role. Find out which ones hold most promise in this at-a-glance summary.
By clicking Accept, you agree to become a member of the UBM Medica Community.